Roche and Exiqon to Co-Market Products for qPCR-based MicroRNA Profiling | GenomeWeb

Roche and Exiqon have agreed to jointly market Roche Applied Science's RealTime ready custom quantitative PCR assays with Exiqon's miRcury LNA Universal RT microRNA qPCR system, the companies said this week.

The co-marketing agreement builds on a licensing agreement related to the same technologies that has been in place since at least 2005, when Roche licensed Exiqon's locked nucleic acid technology to manufacture qPCR assays based on its universal probe library.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.